Here we report a case of a late preterm baby, noted to have asymptomatic hypoglycemia and developed transient metabolic acidosis with hyponatremia and hyperkalemia whilst being treated with continuous infusion of glucagon.
CharshaDS, McKinleyPS, WhitfieldJM.Glucagon infusion for treatment of hypoglycemia: efficacy and safety in sick, preterm infants. Pediatrics. 2003;111(1):220–221. https://doi.org/10.1542/peds.111.1.220
3.
HobanR, TomlinsonC, ChungE, MannJ.Metabolic acidosis during continuous glucagon therapy for neonatal hypoglycemia. Paediatr Child Health. 2023;28(1):24–29. https://doi.org/10.1093/pch/pxac093
4.
BelikJ, MuseyJ, TrussellRA.Continuous infusion of glucagon induces severe hyponatremia and thrombocytopenia in a premature neonate. Pediatrics. 2001;107(3):595–597. https://doi.org/10.1542/peds.107.3.595
5.
LoeuilleGA, RacadotA, VasseurP, VandewalleB.Study of blood and urinary aldosterone levels in newborn, infant and normal children. Pediatrie. 1981;36(5):335–344.
6.
RozancePJ.Pathogenesis, Screening, and Diagnosis of Neonatal Hypoglycemia. In Ted.W., ed. UpToDate; 2023.
7.
AdamkinDH.Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011;127(3). https://doi.org/10.1542/peds.2010-3851
8.
HawdonJM.Identification and management of neonatal hypoglycemia in the full-term infant. British association of perinatal medicine framework for practice, 2017. J Hum Lact. 2019;35(3):521–523. https://doi.org/10.1177/0890334419846128
NarveyMR, MarksSD.The screening and management of newborns at risk for low blood glucose. Paediatr Child Health. 2019;24(8):536–544. https://doi.org/10.1093/pch/pxz134
11.
ThorntonPS, StanleyCA, De LeonDD, . Recommendations from the pediatric endocrine society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr. 2015;167(2):238–245. https://doi.org/10.1016/j.jpeds.2015.03.057
HawdonJM, WeddellA, Aynsley-GreenA, Ward PlattMP.Hormonal and metabolic response to hypoglycaemia in small for gestational age infants. Arch Dis Child. 1993;68(3 Spec No):269–273. https://doi.org/10.1136/adc.68.3_Spec_No.269
14.
DesaiJ, KeyL, SwindallA, GastonK, TalatiAJ.The danger of diazoxide in the neonatal intensive care unit. Ther Adv Drug Saf. 2021;12:204209862110113. https://doi.org/10.1177/20420986211011338
15.
ThorntonP, TruongL, ReynoldsC, HambyT, NedrelowJ.Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism. Horm Res Paediatr. 2019;91(1):25–32. https://doi.org/10.1159/000497458
16.
RozanceJP.Management and outcome of neonatal hypoglycemia. UpToDate. Published online2023.
17.
GioulekaS, GkioulekaM, TsakiridisI, . Diagnosis and management of neonatal hypoglycemia: a comprehensive review of guidelines. Children. 2023;10(7):1220. https://doi.org/10.3390/children10071220
18.
GalsgaardKD.The vicious circle of hepatic glucagon resistance in non-alcoholic fatty liver disease. J Clin Med. 2020;9(12):4049. https://doi.org/10.3390/jcm9124049
19.
MirallesRE, LodhaA, PerlmanM, MooreAM.Experience with intravenous glucagon infusions as a treatment for resistant neonatal hypoglycemia. Arch Pediatr Adolesc Med. 2002;156(10):999. https://doi.org/10.1001/archpedi.156.10.999
20.
HawkesCP, LadoJJ, GivlerS, De LeonDD.The effect of continuous intravenous glucagon on glucose requirements in infants with congenital hyperinsulinism. JIMD Rep. 2019:45:45–50. https://doi.org/10.1007/8904_2018_140
